help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramos, C.
Right arrow Articles by Pardo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramos, C.
Right arrow Articles by Pardo, A.
Am. J. Respir. Cell Mol. Biol., Volume 24, Number 5, May 2001 591-598

Fibroblasts from Idiopathic Pulmonary Fibrosis and Normal Lungs Differ in Growth Rate, Apoptosis, and Tissue Inhibitor of Metalloproteinases Expression

Carlos Ramos, Martha Montaño, Jorge García-Alvarez, Víctor Ruiz, Bruce D. Uhal, Moises Selman, and Annie Pardo

Instituto Nacional de Enfermedades Respiratorias, Mexico DF; Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico; and Department of Physiology, Michigan State University, East Lansing, Michigan


    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by fibroblast proliferation and extracellular matrix accumulation. However, studies on fibroblast growth rate and collagen synthesis have given contradictory results. Here we analyzed fibroblast growth rate by a formazan-based chromogenic assay; fibroblast apoptosis by in situ end labeling (ISEL) and propidium iodide staining; percent of alpha -smooth muscle actin (alpha -SMA) positive cells by fluorescence-activated cell sorter; and alpha 1-(I) collagen, transforming growth factor (TGF)-beta 1, collagenase-1, gelatinases A and B, and tissue inhibitor of metalloproteinase (TIMP)-1, -2, -3, and -4 expression by reverse transcriptase/polymerase chain reaction in fibroblasts derived from IPF and control lungs. Growth rate was significantly lower in IPF fibroblasts compared with controls (13.3 ± 38.5% versus 294.6 ± 57%, P < 0.0001 at 13 d). Conversely, a significantly higher percentage of apoptotic cells was observed in IPF-derived fibroblasts (ISEL: 31.9 ± 7.0% versus 15.5 ± 7.6% from controls; P < 0.008). alpha -SMA analysis revealed a significantly higher percentage of myofibroblasts in IPF samples (62.8 ± 25.2% versus 14.8 ± 11.7% from controls; P < 0.01). IPF fibroblasts were characterized by an increase in pro-alpha 1-(I) collagen, TGF-beta 1, gelatinase B, and all TIMPs' gene expression, whereas collagenase-1 and gelatinase A expression showed no differences. These results suggest that fibroblasts from IPF exhibit a profibrotic secretory phenotype, with lower growth rate and increased spontaneous apoptosis.


    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP) is a progressive and usually lethal lung disorder characterized by fibroblast proliferation and abnormal accumulation of extracellular matrix (ECM) molecules, especially fibrillar collagens (1). An important feature in IPF/UIP is the presence of fibroblast foci, widely dispersed throughout the lung parenchyma (1). Fibroblast foci seem to represent microscopic zones of acute lung injury where fibroblasts migrate, proliferate, and contribute to the accumulation of ECM molecules in the damaged alveolus. Subsequently, abnormal remodeling of lung architecture results from interstitial and intraluminal deposition of connective tissue (2).

However, studies dealing with the proliferative characteristics and collagen synthesis capacity in fibroblasts obtained from normal human lungs and IPF lungs are scant and results have been inconclusive (3). Thus, for example, Jordana and colleagues (3) showed that human lung fibroblasts derived from fibrotic tissues proliferate significantly faster than do those obtained from normal lungs. On the other hand, Raghu and associates (4) found that fibroblast proliferation was highest in cells derived from areas of early fibrosis compared with normal areas, whereas the lowest proliferation was observed in cells obtained from dense fibrosis.

Additionally, fibroblasts are not a homogeneous population, and in the last decade the concept of phenotypic diversity has emerged. Thus, phenotypically distinct populations of lung fibroblasts that differ in surface markers, receptor expression, cytoskeletal arrangement, and cytokine profile have been described (6, 7). In this context we have recently demonstrated significant differences in the growth rate of normal human lung fibroblast subpopulations separated by size, with an inverse relationship between cell size and growth rate (8).

Myofibroblasts are a unique subpopulation of fibroblasts that express features of smooth-muscle differentiation. alpha -Smooth muscle actin (alpha -SMA)-positive fibroblasts increase in IPF lungs and constitute the major component of the fibroblasts' foci (1, 2). In addition, these cells acquire an aggressive phenotype and seem to be the main subset responsible for collagen accumulation (9).

On the other hand, the abnormal ECM remodeling observed in IPF lungs is at least partially due to an imbalance between some components of the matrix metalloproteinase (MMP) family, i.e., collagenase-1 (MMP-1), gelatinases A and B (MMP-2 and -9, respectively), and the tissue inhibitors of metalloproteinase (TIMPs) (10). Fibroblasts are good candidates to play an important role in this aberrant remodeling process because they are responsible for the exaggerated secretion of most of the ECM components; however, their participation through MMP and/or TIMP expression is largely unknown.

In this study we examined the following in lung fibroblasts derived from IPF patients and control human lungs: growth rate; apoptotic index; percent of myofibroblasts; and alpha 1-(I) collagen, MMP-1, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-3, TIMP-4, and transforming growth factor (TGF)-beta gene expression.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Materials

Materials for cell isolation and culture were from GIBCO BRL (Rockville, MD). Trypsin, propidium iodine (PI), and fluorescein isothiocianate (FITC)-conjugated monoclonal antibody (mAb) to alpha -SMA (clone B4A) were obtained from Sigma Chemical Co. (St. Louis, MO). Avidin-FITC, FITC-conjugated antimouse immunoglobulin G, deoxyribonuclease (DNAse)-free ribonuclease (RNAse) (cytometry grade), and proliferation reagent WST-1 were from Boehringer Mannheim (Indianapolis, IN). All other chemicals were of reagent grade.

Fibroblast Isolation and Culture

Primary human lung fibroblasts were obtained in our laboratory as previously described (13). Briefly, fibroblasts were derived from lung tissue obtained from IPF patients (n = 5) by open lung biopsy. IPF was diagnosed as described elsewhere, including the characteristic morphology of UIP (1). Patients (three male and two female; four nonsmokers and one ex-smoker) aged 57 ± 5 yr (mean ± standard deviation [SD]) were inpatients at Instituto Nacional de Enfermedades Respiratorias, Mexico DF, Mexico. Time elapsed to first visit after the beginning of symptoms, usually progressive dyspnea, was 22 ± 6 mo. All patients showed a restrictive functional pattern (forced vital capacity: 57 ± 10% of predicted; total lung capacity: 62 ± 9% of predicted) and hypoxemia at rest (53 ± 7 mmHg; normal values for Mexico City: 59 ± 8 mmHg), worsening with exercise. Lung samples were taken by open lung biopsy usually 1 wk after hospital admission. None of the patients had been treated with corticosteroids or immunosuppressive drugs at the time of biopsy. Control fibroblasts (n = 5) were derived from lungs of patients undergoing lobectomy/pneumonectomy for removal of a primary lung tumor which showed no histologic evidence of disease. Lung fibroblasts were isolated by trypsin dispersion, and cells were grown in Ham's F-12 medium (GIBCO Laboratories, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (GIBCO BRL). Fibroblasts (passages 5-8) were cultured at 37°C in 5% CO2/95% air in T-25 cm2 Falcon flasks, using Ham's F-12 medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin.

Growth Rate Assay

Fibroblasts were plated in 96-well culture plates at a cell density of 15 × 103 cells/well and incubated at 37°C in 5% CO2/95% air in Ham's F-12 medium supplemented with 10% FBS. After 24 h, the medium was replaced using 1% or 10% FBS and the growth rate was followed for 13 d.

Cell number was determined using the cell proliferation reagent WST-1 (Boehringer Mannheim) as previously described (8). WST-1 is a tetrazolium salt cleaved by the mitochondria of viable cells to yield a soluble formazan chromophore. The medium in corresponding wells was replaced with fresh medium, and the dye solution was added to each well according to manufacturer's instructions. Absorbance was measured on an enzyme-linked immunosorbent assay (ELISA) plate reader at a wavelength of 450 nm using a reference wavelength of 620 nm. Absorbance changes were taken as percentage of growth rate increase related to basal values (Day 0).

Flow Cytometry Analysis for alpha -SMA and Apoptosis

Flow cytometry analysis was performed on a Partec CA-III flow cytometer equipped with a 25-mW argon ion laser for excitation at 488 nm. PI fluorescence was acquired through a 610-nm long-pass filter, and fluorescent FITC through an EM 520 band-pass filter. After standardization with fluorescence microspheres (Coulter, Hialeah, FL), amplifier gains were not changed throughout an experiment.

Fibroblasts for cytometry analyses were grown at mid-log phase in culture media supplemented with 10% FBS. Cells were recovered by trypsyn/ethylenediaminetetraacetic acid (EDTA) digestion, centrifuged, and fixed in ice-cold 70% ethanol while shaking for 5 min, and stored at -20°C until assayed.

For apoptosis analysis, a bivariate assay of in situ end labeling (ISEL) versus log forward angle light scatter (FALS, an index of cell size [8]) was performed. Cells were labeled with biotinylated deoxyuridine triphosphate (dUTP) and detected with avidin-FITC as described by Gorczyca and coworkers (14). Briefly, cells were washed with phosphate-buffered saline (PBS) for 10 min at 4°C, and incubated with saline sodium citrate buffer containing 1% bovine serum albumin (BSA) for 45 min at 37°C. After washing with PBS, cells were incubated with 100 µl ISEL buffer containing Bio-dUTP for 2 h at 17°C. Finally, fibroblasts were washed again with PBS and incubated with 100 µl avidin-FITC/ PBS for 45 min at 37°C.

To evaluate alpha -SMA expression, fibroblasts were incubated for 1 h at 37°C with FITC-conjugated monoclonal antihuman alpha -SMA antibody diluted 1:400 in 1% BSA in PBS, pH 7.3, with DNAse-free RNAse (25 µg/ml). DNA distribution experiments were conducted with PI as described earlier (15).

Microscopy and Image Analysis of alpha -SMA

Fibroblasts were grown at mid-log phase in culture media supplemented with 10% fetal calf serum (FCS) and were labeled with antihuman alpha -SMA (clone BA4) antibody in a way similar to that performed for flow cytometry analysis. Photomicrography was accomplished with an Olympus EMT-2 epifluorescence phase-contrast microscope equipped with band-pass filters for detection of FITC and fitted with color and gray-scale charge-coupled device cameras. Cell diameters of alpha -SMA-positive and -negative cells were determined by automated measurement of ferret diameters of 50 cells/group with the image-analysis program MOCHA (Jandel Scientific, San Rafael, CA).

Fluorescence Microscopy for Apoptosis

Detection of apoptotic cells with PI was conducted as described earlier after digestion of ethanol-fixed cells with DNAse-free RNAse in PBS containing 5 µg/ml PI (8, 15). In these assays detached cells were retained by centrifugation of the 24-well culture vessels during fixation with 70% ethanol for at least 30 min at 4°C; red fluorescence intensity (> 590 nm) of chromatin-bound PI is proportional to DNA content, allowing visualization of chromatin condensation. For quantitation, fragmented nuclei were scored as a percentage of total nuclei in a minimum of four microscopic fields per culture vessel; at least four culture vessels per fibroblast strain were scored. Data from three normal and three fibrotic strains were compiled and are reported as means ± SD.

Reverse Transcription/Polymerase Chain Reaction

Total RNA from lung fibroblasts was isolated according the acid guanidium isothiocianate/phenol chloroform extraction method. Complementary DNA (cDNA) from IPF (n = 3) and control (n = 3) fibroblasts was synthesized by reverse transcription of 5 µl total RNA, using a cDNA synthesis kit (GIBCO BRL).

Polymerase chain reaction (PCR) amplification (Perkin-Elmer 9600, Perkin-Elmer, Branchburg, NJ) was performed with a cDNA working mixture in a 25-µl reaction volume containing 20 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2, 200 µM deoxynucleotide triphosphates, 1 µM specific 5' and 3' primers and 1 U Taq DNA polymerase (Perkin-Elmer).

To quantify the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a competitor was constructed by cutting with NcoI an internal fragment of 155 base pairs (bp) of a GAPDH cDNA of originally 1,233 bp cloned in a PBR 322 plasmid. The modified GAPDH cDNA was subsequently religated. The competitor (c) GAPDH sequence was obtained by PCR amplification of the modified plasmid using the primers for GAPDH. The competitor size was 240 bp.

Four-fold serial dilutions of the standard competitor (5, 10, 15, and 20 pg) were coamplified with a constant amount of cellular cDNA (1 µl). Cycling conditions were: 95°C for 10 min for one cycle; 95°C for 30 s, 58°C for 30 s, and 72°C for 120 s for 40 cycles; and the final incubation at 72°C for 7 min. Aliquots (5 µl) of the PCR product were resolved in 1.5% agarose gel containing ethidium bromide. Band intensities were quantitated by scanning densitometry using a Kodak digital science electrophoresis documentation and analysis system 120 (Kodak, Rochester, NY). The logarithm of GAPDH/cGAPDH ratio was plotted as a function of the logarithm of known cGAPDH amount. The point of equivalence represents the concentration of GAPDH in the cDNA sample. Dilutions were performed to reach 50 to 750 fentograms of GAPDH for each amplification as specified in Table 1.

                              
View this table:
[in this window]
[in a new window]
 

TABLE 1
Oligonucleotide primers for PCR amplification

cDNA was amplified with specific primers (16-21, Table 1) by PCR. Amplification conditions for all reactions were done at: 94°C for 5 min for one cycle; 94°C for 30 s, 55 to 60°C for 30 s, and 72° C for 30 s for a number of cycles (Table 1); and the final incubation at 72°C for 5 min. Aliquots (5 µl) of the PCR products were resolved in 1.5% agarose gel containing ethidium bromide. Band intensities were quantitated by scanning densitometry.

Collagen Synthesis Assay

Collagen synthesis was evaluated according to Peterkofsky and Diegelmann (22). Fibroblasts (2.5 × 105 per well) were cultured in six-well tissue culture multiwell plates in Ham's F-12 medium supplemented with 10% FBS. After 24 h, the medium was replaced by fresh serum-free medium containing 15 µCi/ml [3H]proline (New England Nuclear, Boston, MA), 50 µg/ml ascorbic acid, and 50 µg/ml beta -aminopropionitrile. After 6 h labeling, supernatants were collected and dialyzed against distilled water containing protease inhibitors (25 mM N-ethylmaleimide, 0.1 mM phenylmethylsulfonyl fluoride, and 10 mM EDTA) and 0.02% sodium azide. Samples were lyophilized and resuspended in 50 mM Tris-HCl and 10 mM CaCl2 (pH 7.6). Aliquots were incubated with or without 36 µg/ml bacterial collagenase (Sigma type VII) for 3 h at 37°C and precipitated with cold 10% trichloroacetic acid and 0.5% tanic acid. Collagen synthesis was evaluated in the supernatants and noncollagenous proteins in the precipitates after HCl hydrolysis. Samples were counted in a scintillation counter (Beckman LS6000 SE). Collagen synthesis was calculated as: % collagen synthesis = disintegrations per min (dpm) collagen × 100/(dpm noncollagen protein × 5.4) + dpm collagen.

TGF-beta 1 Quantification

Measurement of TGF-beta 1 protein in fibroblast conditioned media was performed by using a commercial sensitive and specific ELISA, following the manufacturer's instructions (R&D Systems, Minneapolis, MN). TGF-beta 1 was expressed as picograms per microgram of protein.

Statistical Analysis

Results are expressed as means ± SD. Comparisons were made using a Student's t test for unpaired observations. Values of P < 0.05 were considered statistically significant.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Growth Rate Analysis

To determine the growth rate of control and IPF-derived fibroblasts, cell number was determined up to 13 d, using the cell proliferation reagent WST-1. As shown in Figure 1A, fibroblasts derived from IPF patients exhibited a significantly lower growth rate when compared with control cells from the fourth day until the end of the experiment (IPF: 13.3 ± 38.5% versus 294.6 ± 57% in controls at 13 d; P < 0.0001). Similar results were obtained when cells were incubated in media containing 10% FCS (Figure 1B).


View larger version (20K):
[in this window]
[in a new window]
 


View larger version (19K):
[in this window]
[in a new window]
 
Figure 1.   Growth rate analysis from primary culture of human lung fibroblasts: normal human lung fibroblasts (control strains, circles); fibroblasts derived from IPF strains (squares). Cells were grown in Ham's nutrient medium supplemented with 1% FCS for 13 d. (A) Fibroblasts incubated in media containing 1% FCS. (B) Fibroblasts incubated in media containing 10% FCS. At the indicated times, cells number was estimated by WST-1 assay (see MATERIALS AND METHODS). Each point represents the mean ± SD of five different primary strains of fibroblasts, each one assayed in quadruplicate; *P < 0.05 at 4 d; **P < 0.01 at 8 and 11 d; ***P < 0.0001 at 13 d (analysis of variance-Bonferroni analysis).

Flow Cytometry Analysis of Apoptosis and alpha -SMA Expression

ISEL of fragmented DNA was used to evaluate the percent of fibroblasts displaying spontaneous apoptosis. Cells cultured in medium supplemented with 10% FCS at mid- log phase were harvested and subjected to cytofluorometric analysis of ISEL in relation to cell size (Figure 2). As shown in Table 2, fibroblasts derived from IPF lungs displayed a significant increase in the percent of apoptotic cells when compared with controls (IPF versus controls: 31.4 ± 6.9% versus 15.0 ± 7.4%; P < 0.008). In addition, the presence of apoptotic cells was analyzed by PI staining (Figures 3A and 3B). As shown in Figure 3C, a significant increase of apoptosis was observed in IPF fibroblasts (430 ± 49% versus 100 ± 16% in controls; P < 0.01).


View larger version (27K):
[in this window]
[in a new window]
 
Figure 2.   Bivariate flow cytometric analysis of ISEL for DNA fragments, versus log FALS (Size) of primary human lung fibroblasts. Cells were grown at mid-log phase in media supplemented with 10% FCS, harvested, and fixed in ice-cold 70% ethanol while shaking. Assay for ISEL is described in MATERIALS AND METHODS. (A) Human fibroblast cell line derived from IPF patient; (B) human control cell line.

                              
View this table:
[in this window]
[in a new window]
 

TABLE 2
Percent of myofibroblasts and apoptotic cells


View larger version (155K):
[in this window]
[in a new window]
 


View larger version (32K):
[in this window]
[in a new window]
 
Figure 3.   Detection of apoptotic fibroblasts with PI under fluorescence microscopy. Subconfluent cultures of fibroblasts were fixed with 70% ethanol in a manner that retained detached cells (see MATERIALS AND METHODS) and were subsequently exposed to 5 µg/ml PI in the presence of DNAse-free RNAse. (A) Normal nuclei in a control fibroblast strain. (B) Normal and fragmented nuclei (arrowheads) containing condensed chromatin, indicative of apoptosis in an IPF fibroblast strain. (C) Quantitation of apoptotic fibroblasts by the PI assay. Fragmented nuclei were scored as a percentage of total nuclei as described in MATERIALS AND METHODS. Data are means ± SD from three normal and three fibrotic strains compiled. *P < 0.01.

The proportion of alpha -SMA immunoreactive cells was analyzed by immunocytochemistry followed by microscopy image analysis and cytometry analysis in relation to DNA content, as shown in Figure 4. As seen in Table 2, several strains of lung fibroblasts derived from IPF patients showed a significant increase in the percent of alpha -SMA- positive cells when compared with control lung fibroblasts (IPF versus controls: 62.8 ± 25.2 versus 14.8 ± 11.6%; P < 0.01).


View larger version (39K):
[in this window]
[in a new window]
 


View larger version (33K):
[in this window]
[in a new window]
 
Figure 4.   Relationship of alpha -SMA immunoreactivity to DNA content in human primary lung fibroblasts. Cells were cultured to mid-log phase with 10% FCS, washed, harvested, and fixed in ice-cold 70% ethanol while stirring for flow cytometry detection. Fibroblasts were incubated with FITC-conjugated mAbs to alpha -SMA (anti-alpha -SMA; see MATERIALS AND METHODS) and subjected to cytometry analysis versus DNA content by means of PI stain. (A') A human fibroblast cell line derived from an IPF patient. (B') A normal human lung fibroblast. Left: immunofluorescent analysis of the same cell lines shown on the right. (A) Human fibroblast cell line derived from an IPF patient. (B) Control fibroblasts. (C) Negative control omitting the antihuman alpha -SMA antibody.

Additionally, the cell diameters of alpha -SMA-positive and -negative cells were determined by automated measurement of ferret diameters of 50 cells/group with the image-analysis program MOCHA. Results showed that in both IPF and control fibroblast strains, cells immunoreactive to alpha -SMA exhibited a significantly higher diameter than did negative cells (IPF: 38.1 ± 8.2 µm versus 26.9 ± 7.4 µm, P < 0.05; controls: 35.8 ± 7.0 µm versus 25.7 ± 5.8 µm, P < 0.05). This result was consistent with immunocytochemical observation where alpha -SMA immunoreactive cells appeared larger than negative cells (Figures 4A and 4B).

IPF and Control Fibroblast Gene Expression

Semiquantitative assessment of messenger RNA (mRNA) of selected molecules expressed by IPF and control fibroblasts was done by serial dilutions of cDNA samples adjusted to equal quantified housekeeping gene GAPDH. Densities of bands of PCR products achieved with these primers were analyzed by agarose gel electrophoresis (Figure 5). GAPDH band intensities were quantitated by scanning densitometry (controls: 5,314 ± 96; IPF fibroblasts: 5,377 ± 85), demonstrating that the DNA used from different cell lines was similar.


View larger version (42K):
[in this window]
[in a new window]
 


View larger version (49K):
[in this window]
[in a new window]
 
Figure 5.   Expression of mRNA by three control and three IPF fibroblasts using a semiquantitative RT-PCR methodology (see MATERIALS AND METHODS). Total fibroblast RNA was extracted and subjected to RT-PCR amplification using specific primers (Table 1). PCR products were electrophoresed and visualized by ethidium bromide staining. (A) alpha 1-(I) collagen, TGF-beta 1, collagenase-1, gelatinases A and B, and the housekeeping gene GAPDH. (B) TIMP-1, -2, -3, and -4, and GAPDH.

IPF-derived fibroblasts consistently revealed a higher expression of alpha 1-(I) collagen gene as compared with control fibroblasts (Figure 5A). The expression increased almost 2-fold when quantitated by scanning densitometry (9,418 ± 1,217 versus 5,173 ± 1,559; P < 0.02). When these cell lines were analyzed for collagen synthesis a similar result was observed (53.1 ± 5.2% versus 28.6 ± 3.7%; P < 0.01). Concerning TGF-beta 1 expression (Figure 5A), mRNA transcripts were usually more abundant in IPF than in control fibroblasts (12,881 ± 2,033 versus 6,902 ± 2,782; P < 0.05); however, at the protein level, results were heterogeneous and no differences were observed (96 ± 23 versus 120 ± 34 pg/mg protein).

Collagenase-1 (MMP-1) was expressed by one out of three control cell strains and equally by one from three IPF-derived fibroblast cell strains with no difference in the net intensity of the band in the collagenase-expressing cell lines. No significant differences were found among fibroblasts expressing gelatinase A (MMP-2) (3,922 ± 664 in normal versus 6,037 ± 1,641 in IPF fibroblasts). By contrast, gelatinase B (MMP-9) was expressed in two out of three IPF-derived strains (30,414 ± 1,416) and faintly (3,615) by one out of three control cell lines (Figure 5A).

Results of reverse transcriptase (RT-PCR) for all four TIMPs are illustrated in Figure 5B. TIMP-1 revealed a 2-fold increase in IPF compared with control fibroblasts (75,195 ± 10,119 versus 38,479 ± 13,846; P < 0.02). TIMP-2 was also highly expressed in IPF fibroblasts showing a 2-fold increase in net intensity in IPF as compared with controls (20,935 ± 6,451 versus 9,449 ± 4,322; P = 0.05). Likewise, TIMP-3 and TIMP-4 were mainly expressed in IPF-derived fibroblasts and faintly detectable in one control cell strain.

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

IPF is a progressive and usually fatal lung disorder characterized by the occurrence of widely scattered small clusters of fibroblasts, presumably provoked by multiple microscopic lung injuries, and abnormal tissue remodeling (1).

A growing body of evidence has demonstrated that there is phenotypic and behavioral heterogeneity among tissue fibroblasts. Myofibroblasts, which express features of smooth-muscle differentiation, constitute one of these subpopulations and are usually increased in human and experimental lung fibrosis (2, 9).

In the present study, fibroblasts derived from IPF lungs displayed a marked increase in the percentage of myofibroblasts, paralleling the in vivo observations. As examined by fluorescence-activated cell sorter and immunocytochemistry, most of the fibroblasts derived from IPF lungs expressed alpha -SMA. The cell origin of lung myofibroblasts remains unknown, but interstitial fibroblasts and smooth muscle-like cells of the alveolar duct septal tips are considered as a potential source (23). Increased myofibroblasts in the multiple fibroblast foci of IPF lungs may have a number of deleterious consequences, primarily contributing to active parenchymal contraction, decreased compliance, and distorted architecture (2). Actually, myofibroblasts play a critical role in healing because they express high levels of alpha -SMA, form tight adhesions to the substrate, and arrange the stress fibers along the long axis, facilitating tissue contraction and reducing the amount of denuded surface area of wounded tissue (24). In addition, myofibroblasts produce apoptotic factor(s) for alveolar epithelial cells in vitro (25), and have been localized close to denuded alveolar epithelium in vivo (26). Moreover, it has been suggested that myofibroblasts may be responsible for most of the increased lung collagen gene expression in pulmonary fibrosis (9). Nevertheless, this last observation had not been documented in vitro. Raghu and colleagues (5) found that fibroblasts from normal and fibrotic lungs synthesize similar amounts of collagen even when stimulated with TGF-beta . In our study, however, fibroblasts derived from IPF lungs, usually presenting high proportions of alpha -SMA-positive cells, expressed higher levels of type I collagen mRNA and synthesized higher amounts of collagen compared with normal lung fibroblasts.

On the other hand, IPF fibroblasts showed a marked decrease of growth rate when compared with lung fibroblasts derived from normal subjects. The cell kinetic assay showed a marked difference from the fourth day on. This finding differs from those previously reported. Thus, Jordana and associates (3) showed that primary fibroblasts derived from IPF patients proliferated faster than did normal lung fibroblasts; whereas Raghu and coworkers (4), who obtained fibroblasts from different areas of the same fibrotic lung, found a higher rate of proliferation in cells derived from inflammatory areas and the lowest in fibroblasts from dense fibrotic scars. Given the new histologic classification of IPF (1), it is not certain whether IPF fibroblasts in those studies were obtained from UIP cases.

Our results substantiate unpublished observations found repeatedly over many years in our laboratory. Usually, fibroblast strains derived from IPF lungs are very difficult to grow in vitro and exhibit a limited number of duplications. The reduced growth rate of the IPF fibroblasts could have several possible explanations. Thus, for example, it has been shown that rat lung myofibroblast differentiation in vitro results in reduced telomerase activity (27). The decreased expression of this enzyme may account for a reduced proliferative capacity. Likewise, we have previously demonstrated that myofibroblasts, when separated by gravity sedimentation, are usually large cells that grow markedly slower than intermediate or small size fibroblasts (8). Coincidentally, in this study we also observed that the diameters of the alpha -SMA-positive cells, independently if derived from normal or IPF lungs, were significantly larger than those of alpha -SMA-negative cells.

In addition, slower growth rate may be also explained by an increase in programmed cell death. Our findings support this notion because IPF fibroblasts exhibited a higher basal rate of spontaneous apoptosis than did normal cells. In studies of primary fibroblasts isolated from normal human lung, Akamine and colleagues (6) identified two subpopulations which were isolated on the basis of differential expression of the receptor for C1q, one of the first subcomponents of complement. The fibroblast subsets separated by C1q receptor expression displayed two distinct morphologies: spindle-shaped cells with elongated processes (high binding), or larger and more flattened cells (6). The subgroups also differed in rates of proliferation and especially collagen synthesis, both under basal conditions and after inhibition by interferon-gamma or stimulation by TGF-beta . More interesting in the context of our findings, the low C1q-binding subset also displayed a poor rate of growth in culture despite containing a higher percentage of cycling cells identified by flow cytometry (6).

This paradox might be explained by a higher rate of spontaneous apoptosis within this subpopulation, which exhibits the same morphologic characteristics (large and flat) as the "large" subgroup identified in our earlier work (8).

Regardless, in this report we showed that IPF fibroblast isolates contain an increased subpopulation of myofibroblasts and exhibit decreased proliferative capacity and an increased rate of spontaneous apoptosis. A number of cytokines might participate in the induction of this apoptosis, including interleukin-1beta , which has been reported to induce apoptosis and inhibit cell proliferation (28). In addition, the increased basal apoptosis might be related to the production by myofibroblasts of angiotensin peptides (29), which induce apoptosis in a variety of cell types, including alveolar epithelial cells of the lung (29, 30). With regard to the molecules analyzed in this study, although primarily related to ECM remodeling, some of them may also contribute to increased apoptosis. Particularly, overexpression of TIMP-3 induces programmed cell death in a variety of cell types (31). Inhibition of tumor necrosis factor-alpha -converting enzyme may account at least partially for its ability to induce apoptosis (31).

The determination of which of these factors is involved in the induction of fibroblast apoptosis, and which phenotypes within the lung fibroblast isolate undergo apoptosis, will be an interesting topic for future experiments.

The final stage of IPF is an extensive structural disorganization of the lung parenchyma with the subsequent progressive loss of the alveolar-capillary units. The molecular mechanisms behind this erratic tissue remodeling that results in an exaggerated ECM accumulation have not been elucidated but likely involve a loss in the highly regulated balance between MMPs and TIMPs (10). In this context there were no differences in collagenase-1 mRNA expression, which corroborates previous findings with MMP-1 protein levels in IPF and control fibroblasts (32). With regard to gelatinases, MMP-2 has been shown to be constitutively expressed in lung fibroblasts and we did not find differences in IPF and normal lung-derived cells. However, normal lung fibroblasts usually do not express MMP-9 in vitro and thus our recent finding---corroborated in this study---that fibroblasts obtained from IPF lungs strongly expressed the MMP-9 transcript was quite interesting (12). Further, the expression of gelatinase B was closely related with the percent of myofibroblasts (12). Gelatinase B expression may have a role in basement membrane disruption and fibroblast migration into the alveolar spaces.

The gene expression of all four TIMPs was usually increased in fibroblasts derived from IPF lungs. Although different TIMPs bind tightly to most MMPs, differences in inhibitory properties, expression patterns, and other properties---such as association with latent MMPs, cell growth- promoting activity, cell survival-promoting activity, and apoptosis---have been reported (31, 33). In this context, upregulation of TIMP gene expression could contribute to a prevailing lung fibrotic microenvironment by inhibiting MMP activity and matrix degradation; supporting this point of view, we recently found in vivo that in IPF lungs there is higher interstitial expression of TIMPs compared with collagenases (12). On the other hand, because TIMPs may play a role in regulating apoptosis or cell survival, the increase of TIMP expression may also contribute to the pathogenic processes observed in IPF lungs by either increasing proliferation of some cell populations or inducing the death of others. In this context, it is interesting to emphasize that TIMP-2 is almost exclusively expressed by fibroblasts/myofibroblasts in the characteristic fibroblast foci considered to be the sites of ongoing alveolar epithelial injury and activation associated with evolving fibrosis (11, 12). Fibroblast TIMP-2 expression could be associated with collagenase inhibitory effect, but also with activation of latent gelatinase A and stimulation of fibroblast proliferation. TIMP-3 is singular because it binds strongly to insoluble extracellular components, mainly heparan sulfate. It has been observed to have antiadhesive properties in fibroblasts, and TIMP-3 overexpression can induce apoptosis (31). TIMP-3 is the only TIMP to inhibit members of the ADAM (a disintegrin and metalloprotease domain) and to restrain shedding of L-selectin (31). Interestingly, it has been reported that the levels of TIMP-3 mRNA were elevated in systemic sclerosis fibroblast cell strains (34). Studies on TIMP-4 are scanty and their functional activities, besides MMP inhibition, are essentially unknown. Recent evidence demonstrates a temporal relationship between upregulation of TIMP-4 and the onset of collagen deposition in injured arterial walls, suggesting an important role in the proteolytic balance of the vasculature (35).

Certainly, other cell types besides fibroblasts/myofibroblasts may play a role in the protease-antiprotease imbalance in IPF. Thus, resident cells (i.e., alveolar epithelial cells and endothelial cells) as well as those derived from the inflammatory response are able to produce different MMPs and TIMPs in vivo. Particularly, MMP-1, MMP-2, MMP-9, and TIMP-2 have been detected in epithelial cells close to fibroblast foci. MMP-1 has also been observed in alveolar macrophages, MMP-9 in neutrophils, TIMP-1 and TIMP-3 in interstitial macrophages, and TIMP-4 in plasma-cells (11). Therefore, during the development of IPF, ECM remodeling is regulated by a complex interplay among epithelial and endothelial cells, fibroblasts, and inflammatory cells, and the ECM in the local mielieu.

In summary, although the number of fibroblast strains explored in this study is small, our in vitro findings correlate with some previous in vivo observations and suggest that fibroblasts/myofibroblasts from IPF lungs exhibit a profibrotic secretory phenotype with lower growth rate and increased spontaneous apoptosis.

    Footnotes

Address correspondence to: Annie Pardo, Ph.D., Apartado Postal 21-630, Coyoacán , Mexico DF 04000, Mexico.

(Received in original form August 21, 2000 and in revised form November 21, 2000).

Abbreviations: alpha -smooth muscle actin, alpha -SMA; base pair(s), bp; complementary DNA, cDNA; competitor GAPDH, cGAPDH; deoxyribonuclease, DNase; extracellular matrix, ECM; fetal bovine serum, FBS; fetal calf serum, FCS; fluorescein isothiocyanate, FITC; glyceraldehyde-3-phosphate dehydrogenase, GAPDH; idiopathic pulmonary fibrosis, IPF; in situ end labeling, ISEL; matrix metalloproteinase, MMP; messenger RNA, mRNA; phosphate-buffered saline, PBS; polymerase chain reaction, PCR; propidium iodide, PI; ribonuclease, RNase; reverse transcriptase, RT; standard deviation, SD; transforming growth factor, TGF; tissue inhibitor of metalloproteinase, TIMP; usual interstitial pneumonia, UIP.
    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Katzenstein, A. L. A., and J. L. Myers. 1998. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 157: 1301-1315 [Free Full Text].

2. Kuhn, C., and J. A. McDonald. 1991. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol. 138: 1257-1265 [Abstract].

3. Jordana, M., J. Schulman, C. McSharry, L. B. Irving, M. T. Newhouse, G. Jordana, and J. Gauldie. 1988. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am. Rev. Respir. Dis. 137: 579-584 [Medline].

4. Raghu, G., Y. Y. Chen, V. Rusch, and P. S. Rabinovitch. 1988. Differential proliferation of fibroblasts cultured from normal and fibrotic human Lung. Am. Rev. Respir. Dis. 138: 703-708 [Medline].

5. Raghu, G., S. Masta, D. Meyers, and A. S. Narayanan. 1989. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta . Am. Rev. Respir. Dis. 140: 95-100 [Medline].

6. Akamine, A., G. Raghu, and S. Narayanan. 1992. Human lung subpopulations with different C1q binding and functional properties. Am. J. Respir. Cell Mol. Biol. 6: 382-389 .

7. Phipps, R. P. 1992. Pulmonary Fibroblast Heterogeneity. CRC Press, Boca Raton, FL.

8. Uhal, B. D., C. Ramos, I. Joshi, A. Bifero, A. Pardo, and M. Selman. 1998. Cell size, cell cycle, and alpha -smooth muscle actin expression by primary human lung fibroblasts. Am. J. Physiol. 275: L998-L1005 [Abstract/Free Full Text].

9. Zhang, K., M. D. Rekhter, D. Gordon, and S. H. Phan. 1994. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. Am. J. Pathol. 145: 114-125 [Abstract].

10. Hayashi, T., W. G. Stetler-Stevenson, M. V. Fleming, N. Fishback, M. N. Koss, L. A. Liotta, V. J. Ferrans, and W. D. Travis. 1996. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am. J. Pathol. 149: 1241-1256 [Abstract].

11. Fukuda, Y., M. Ishizaki, S. Kudoh, M. Kitaichi, and N. Yamanaka. 1998. Localization of matrix metalloproteinases-1, -2, and -9, and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab. Invest. 78: 687-698 [Medline].

12. Selman, M., V. Ruiz, S. Cabrera, L. Segura, R. Ramírez, R. Barrios, and A. Pardo. 2000. TIMP 1, 2, 3 and 4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am. J. Physiol. 279: L562-L574 [Abstract/Free Full Text].

13. Becerril, C., A. Pardo, M. Montaño, C. Ramos, R. Ramírez, and M. Selman. 1999. Acidic fibroblast growth factor (FGF-1) induces an antifibrogenic phenotype in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 20: 1020-1027 [Abstract/Free Full Text].

14. Gorczyca, W., J. Gong, and Z. Darzynkiewicz. 1993. Detection of DNA strand breaks in individual apoptotic cells by in situ terminal deoxynucleotidyl transferase and nick translation assay. Cancer Res. 53: 1945-1951 [Abstract/Free Full Text].

15. Uhal, B. D., and D. E. Rannels. 1991. DNA distribution analysis of Type II pneumocyte by laser flow cytometry: technical considerations. Am. J. Physiol. 261: L296-L306 [Abstract/Free Full Text].

16. Janowska-Wieczorek, A., L. A. Marquez, A. Matsuzaki, H. Hashmi, R. Haroon, L. M. Laratt, L. M. Boshkov, A. R. Turner, M. C. Zhang, D. R. Edwards, and A. E. Kossokowska. 1992. Expression of matrix metalloproteinases (MMP-2 and 9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br. J. Haematol. 105: 402-411 .

17. Takagi, M., S. Santavirta, H. Ida, M. Ishii, K. Akimoto, K. Saotome, and Y. T. Konttinen. 1998. The membrane-type-matrix metalloproteinase/matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 system in periprosthetic connective-tissue remodeling in loose total hip prostheses. Lab. Invest. 78: 735-742 [Medline].

18. Finlay, G. A., L. R. O'Driscoll, K. J. Russell, E. M. D'Arcy, J. B. Masterson, M. X. FitzGerald, and C. M. O'Connor. 1997. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. Care Med. 156: 240-247 [Abstract/Free Full Text].

19. Lemjabbor, H., P. Gosset, E. Lechapt-Zatcman, M. L. Franco-Montoya, B. Wallaert, A. Harf, and C. Lafuma. 1999. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 20: 903-913 [Abstract/Free Full Text].

20. Thur, J., R. Nischt, T. Krieg, and N. Hunzelmann. 1996. Quantitative analysis of alpha 1(I) procollagen transcripts in vivo by competitive polymerase chain reaction. Matrix Biol. 15: 49-52 [Medline].

21. Napoli, J., D. Prentice, C. Niinami, A. Bishop, P. Desmond, and G. W. McCaughan. 1997. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta  in bile duct ligated rat model of cirrhosis. Hepatology 26: 624-633 [Medline].

22. Peterkofsky, B., and R. Diegelmann. 1971. Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry 10: 988-994 [Medline].

23. Leslie, K. O., J. Mitchell, and R. Low. 1992. Lung myofibroblasts. Cell Motil. Cytoskeleton 22: 92-98 [Medline].

24. Racine-Samson, L., D. C. Rockey, and D. M. Bissell. 1997. The role of alpha 1 beta 1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J. Biol. Chem. 272: 30911-30917 [Abstract/Free Full Text].

25. Uhal, B., I. Joshi, S. Mundle, A. Raza, A. Pardo, and M. Selman. 1995. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am. J. Physiol. 269: L819-L828 [Abstract/Free Full Text].

26. Uhal, B. D., I. Joshi, W. F. Hughes, C. Ramos, A. Pardo, and M. Selman. 1998. Alveolar epithelial cell death adjacent to underline myofibroblasts in advanced fibrotic human lung. Am. J. Physiol. 275: L1192-L1199 [Abstract/Free Full Text].

27. Nozaky, Y., and S. Phan. 1999. Rat lung myofibroblast differentiation results in reduced telomerase activity. Am. J. Respir. Crit. Care Med. 159: A929 .

28. Zhang, H. Y., M. Gharaee-Kermani, and S. H. Phan. 1997. Regulation of lung fibroblast alpha -smooth muscle actin expression, contractile phenotype, and apoptosis by IL-1beta . J. Immunol. 158: 1392-1399 [Abstract].

29. Wang, R., C. Ramos, I. Joshi, A. Zagariya, O. Ibarra-Sunga, A. Pardo, M. Selman, and B. D. Uhal. 1999. Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am. J. Physiol. 277: L1158-L1164 [Abstract/Free Full Text].

30. Kajstura, J., E. Cigola, A. Malhotra, P. Li, W. Cheng, L. G. Meggs, and P. Anversa. 1997. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J. Mol. Cell. Cardiol. 29: 859-870 [Medline].

31. Brew, K., D. Dinakarpandian, and H. Nagase. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477: 267-283 [Medline].

32. Pardo, A., M. Selman, R. Ramírez, C. Ramos, M. Montaño, G. Stricklin, and G. Raghu. 1992. Production of collagenase and tissue inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human lungs. Chest 102: 1085-1089 [Abstract/Free Full Text].

33. Gómez, D., D. Alonso, U. Yoshiji, and U. P. Thorgeirsson. 1997. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74: 111-122 [Medline].

34. Mattila, L., K. Airola, M. Ahonen, M. Hietarinta, C. Black, U. Saarialho-Kere, and V. M. Kahari. 1998. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J. Invest. Dermatol. 110: 416-421 [Medline].

35. Dollery, C. M., J. R. McEwan, M. Wang, Q. A. Sang, Y. E. Liu, and Y. E. Shi. 1999. TIMP-4 is regulated by vascular injury in rats. Circ. Res. 84: 498-504 [Abstract/Free Full Text].





This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
L. J. Vuga, A. Ben-Yehudah, E. Kovkarova-Naumovski, T. Oriss, K. F. Gibson, C. Feghali-Bostwick, and N. Kaminski
WNT5A Is a Regulator of Fibroblast Proliferation and Resistance to Apoptosis
Am. J. Respir. Cell Mol. Biol., November 1, 2009; 41(5): 583 - 589.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. A. Queisser, F. M. Kouri, M. Konigshoff, M. Wygrecka, U. Schubert, O. Eickelberg, and K. T. Preissner
Loss of RAGE in Pulmonary Fibrosis: Molecular Relations to Functional Changes in Pulmonary Cell Types
Am. J. Respir. Cell Mol. Biol., September 1, 2008; 39(3): 337 - 345.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
H. Xia, D. Diebold, R. Nho, D. Perlman, J. Kleidon, J. Kahm, S. Avdulov, M. Peterson, J. Nerva, P. Bitterman, et al.
Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis
J. Exp. Med., July 7, 2008; 205(7): 1659 - 1672.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Respir DisHome page
P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini
Review: New perspectives in the treatment of idiopathic pulmonary fibrosis
Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93.
[Abstract] [PDF]


Home page
J. Immunol.Home page
M. Abel and H. Vliagoftis
Mast Cell-Fibroblast Interactions Induce Matrix Metalloproteinase-9 Release from Fibroblasts: Role for IgE-Mediated Mast Cell Activation
J. Immunol., March 1, 2008; 180(5): 3543 - 3550.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
J. C. Horowitz, D. S. Rogers, R. H. Simon, T. H. Sisson, and V. J. Thannickal
Plasminogen Activation Induced Pericellular Fibronectin Proteolysis Promotes Fibroblast Apoptosis
Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 78 - 87.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. Konigshoff, A. Wilhelm, A. Jahn, D. Sedding, O. V. Amarie, B. Eul, W. Seeger, L. Fink, A. Gunther, O. Eickelberg, et al.
The Angiotensin II Receptor 2 Is Expressed and Mediates Angiotensin II Signaling in Lung Fibrosis
Am. J. Respir. Cell Mol. Biol., December 1, 2007; 37(6): 640 - 650.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. Burstein, X.-Y. Qi, Y.-H. Yeh, A. Calderone, and S. Nattel
Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: A novel consideration in atrial remodeling
Cardiovasc Res, December 1, 2007; 76(3): 442 - 452.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
D. Kass, R. S. Bridges, A. Borczuk, and S. Greenberg
Methionine Aminopeptidase-2 as a Selective Target of Myofibroblasts in Pulmonary Fibrosis
Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 193 - 201.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
N. I. Chaudhary, G. J. Roth, F. Hilberg, J. Muller-Quernheim, A. Prasse, G. Zissel, A. Schnapp, and J. E. Park
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
Eur. Respir. J., May 1, 2007; 29(5): 976 - 985.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
E. M. Pierce, K. Carpenter, C. Jakubzick, S. L. Kunkel, K. R. Flaherty, F. J. Martinez, and C. M. Hogaboam
Therapeutic Targeting of CC Ligand 21 or CC Chemokine Receptor 7 Abrogates Pulmonary Fibrosis Induced by the Adoptive Transfer of Human Pulmonary Fibroblasts to Immunodeficient Mice
Am. J. Pathol., April 1, 2007; 170(4): 1152 - 1164.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
Y. Y. Sanders, P. Kumbla, and J. S. Hagood
Enhanced Myofibroblastic Differentiation and Survival in Thy-1(-) Lung Fibroblasts
Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 226 - 235.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. Ramos, M. Montano, C. Becerril, J. Cisneros-Lira, L. Barrera, V. Ruiz, A. Pardo, and M. Selman
Acidic fibroblast growth factor decreases {alpha}-smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts
Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L871 - L879.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
I. Sinuani, Z. Averbukh, I. Gitelman, M. J. Rapoport, J. Sandbank, M. Albeck, B. Sredni, and J. Weissgarten
Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10-induced TGF-beta secretion: effect of the immunomodulator AS101 on this process
Am J Physiol Renal Physiol, August 1, 2006; 291(2): F384 - F394.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M Molina-Molina, A Serrano-Mollar, O Bulbena, L Fernandez-Zabalegui, D Closa, A Marin-Arguedas, A Torrego, J Mullol, C Picado, and A Xaubet
Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis
Thorax, July 1, 2006; 61(7): 604 - 610.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
N. I. Chaudhary, A. Schnapp, and J. E. Park
Pharmacologic Differentiation of Inflammation and Fibrosis in the Rat Bleomycin Model
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 769 - 776.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. Matsuyama, M. Watanabe, Y. Shirahama, H. Mitsuyama, I. Higashimoto, M. Osame, and K. Arimura
Discoidin Domain Receptor 1 Contributes to the Survival of Lung Fibroblast in Idiopathic Pulmonary Fibrosis
Am. J. Pathol., March 1, 2006; 168(3): 866 - 877.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. Fredriksson, X. D. Liu, J. Lundahl, J. Klominek, S. I. Rennard, and C. M. Skold
Red blood cells increase secretion of matrix metalloproteinases from human lung fibroblasts in vitro
Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L326 - L333.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
V. J. Thannickal and J. C. Horowitz
Evolving concepts of apoptosis in idiopathic pulmonary fibrosis.
Proceedings of the ATS, January 1, 2006; 3(4): 350 - 356.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
C. Agostini and C. Gurrieri
Chemokine/Cytokine cocktail in idiopathic pulmonary fibrosis.
Proceedings of the ATS, January 1, 2006; 3(4): 357 - 363.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
E S Choi, E M Pierce, C Jakubzick, K J Carpenter, S L Kunkel, H Evanoff, F J Martinez, K R Flaherty, B B Moore, G B Toews, et al.
Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia
J. Clin. Pathol., January 1, 2006; 59(1): 28 - 39.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
J.-B. Park, J.-K. Lee, S.-J. Park, and K. D. Riew
Hypertrophy of Ligamentum Flavum in Lumbar Spinal Stenosis Associated with Increased Proteinase Inhibitor Concentration
J. Bone Joint Surg. Am., December 1, 2005; 87(12): 2750 - 2757.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
X. Liu, S. Q. Sun, and R. S. Ostrom
Fibrotic Lung Fibroblasts Show Blunted Inhibition by cAMP Due to Deficient cAMP Response Element-Binding Protein Phosphorylation
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 678 - 687.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. L. Chunn, J. G. Molina, T. Mi, Y. Xia, R. E. Kellems, and M. R. Blackburn
Adenosine-Dependent Pulmonary Fibrosis in Adenosine Deaminase-Deficient Mice
J. Immunol., August 1, 2005; 175(3): 1937 - 1946.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. C. Grutters and R. M. du Bois
Genetics of fibrosing lung diseases
Eur. Respir. J., May 1, 2005; 25(5): 915 - 927.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Z. Zhou, R. Song, C. L. Fattman, S. Greenhill, S. Alber, T. D. Oury, A. M.K. Choi, and D. Morse
Carbon Monoxide Suppresses Bleomycin-Induced Lung Fibrosis
Am. J. Pathol., January 1, 2005; 166(1): 27 - 37.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. L. Watts and M. A. Spiteri
Connective tissue growth factor expression and induction by transforming growth factor-{beta} is abrogated by simvastatin via a Rho signaling mechanism
Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1323 - L1332.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
E. S. Choi, C. Jakubzick, K. J. Carpenter, S. L. Kunkel, H. Evanoff, F. J. Martinez, K. R. Flaherty, G. B. Toews, T. V. Colby, E. A. Kazerooni, et al.
Enhanced Monocyte Chemoattractant Protein-3/CC Chemokine Ligand-7 in Usual Interstitial Pneumonia
Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 508 - 515.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Zhou, J. S. Hagood, and J. E. Murphy-Ullrich
Thy-1 Expression Regulates the Ability of Rat Lung Fibroblasts to Activate Transforming Growth Factor-{beta} in Response to Fibrogenic Stimuli
Am. J. Pathol., August 1, 2004; 165(2): 659 - 669.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
N. Khalil and R. O'Connor
Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment
Can. Med. Assoc. J., July 20, 2004; 171(2): 153 - 160.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
K. Williams, D. Malarkey, L. Cohn, D. Patrick, J. Dye, and G. Toews
Identification of Spontaneous Feline Idiopathic Pulmonary Fibrosis: Morphology and Ultrastructural Evidence for a Type II Pneumocyte Defect
Chest, June 1, 2004; 125(6): 2278 - 2288.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
C. Jakubzick, E. S. Choi, K. J. Carpenter, S. L. Kunkel, H. Evanoff, F. J. Martinez, K. R. Flaherty, G. B. Toews, T. V. Colby, W. D. Travis, et al.
Human Pulmonary Fibroblasts Exhibit Altered Interleukin-4 and Interleukin-13 Receptor Subunit Expression in Idiopathic Interstitial Pneumonia
Am. J. Pathol., June 1, 2004; 164(6): 1989 - 2001.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Montano, C. Beccerril, V. Ruiz, C. Ramos, R. H. Sansores, and G. Gonzalez-Avila
Matrix Metalloproteinases Activity in COPD Associated With Wood Smoke
Chest, February 1, 2004; 125(2): 466 - 472.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Cisneros-Lira, M. Gaxiola, C. Ramos, M. Selman, and A. Pardo
Cigarette smoke exposure potentiates bleomycin-induced lung fibrosis in guinea pigs
Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L949 - L956.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
N. Kaminski, J. A. Belperio, P. B. Bitterman, L. Chen, S. W. Chensue, A. M.K. Choi, S. Dacic, J. H. Dauber, R. M. du Bois, J. J. Enghild, et al.
Idiopathic Pulmonary Fibrosis
Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): S1 - 105.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
E. S. White, V. J. Thannickal, S. L. Carskadon, E. G. Dickie, D. L. Livant, S. Markwart, G. B. Toews, and D. A. Arenberg
Integrin {alpha}4{beta}1 Regulates Migration across Basement Membranes by Lung Fibroblasts: A Role for Phosphatase and Tensin Homologue Deleted on Chromosome 10
Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 436 - 442.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. P. Moodley, A. K. Scaffidi, N. L. Misso, C. Keerthisingam, R. J. McAnulty, G. J. Laurent, S. E. Mutsaers, P. J. Thompson, and D. A. Knight
Fibroblasts Isolated from Normal Lungs and Those with Idiopathic Pulmonary Fibrosis Differ in Interleukin-6/gp130-Mediated Cell Signaling and Proliferation
Am. J. Pathol., July 1, 2003; 163(1): 345 - 354.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
N. Murai, K. Nagai, H. Fujisawa, K. Hatanaka, M. Kawamura, and Y. Harada
Concurrent evolution and resolution in an acute inflammatory model of rat carrageenin-induced pleurisy
J. Leukoc. Biol., April 1, 2003; 73(4): 456 - 463.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
J. J. Atkinson and R. M. Senior
Matrix Metalloproteinase-9 in Lung Remodeling
Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 12 - 24.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. G. Crystal, P. B. Bitterman, B. Mossman, M. I. Schwarz, D. Sheppard, L. Almasy, H. A. Chapman, S. L. Friedman, T. E. King Jr., L. A. Leinwand, et al.
Future Research Directions in Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group
Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 236 - 246.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. K. Winkler and J. L. Fowlkes
Metalloproteinase and growth factor interactions: do they play a role in pulmonary fibrosis?
Am J Physiol Lung Cell Mol Physiol, July 1, 2002; 283(1): L1 - L11.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramos, C.
Right arrow Articles by Pardo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramos, C.
Right arrow Articles by Pardo, A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2001 American Thoracic Society.